We tested 143 isolates of staphylococci with vancomycin by the National Committee for Clinical Laboratory Standards broth microdilution (BMD) reference method and compared the results to those generated using the Vitek automated system (GPS-105 and GPS-107 cards and version 7.01 software). For ten isolates, the vancomycin MICs by BMD were 8 g/ml. By Vitek, the vancomycin MICs ranged from 2 to 16 g/ml. Vancomycin MICs of Ն32 g/ml were reported for two additional isolates by Vitek; however, the MICs decreased to Յ0.5 g/ml on retesting. By BMD, the vancomycin MICs for both isolates were 1 g/ml. While the modal vancomycin MIC results by BMD for S. aureus and coagulase-negative staphylococci (CoNS) were both 1 g/ml, Vitek results showed a mode of Յ0.5 g/ml for S. aureus, and a mode of 2 g/ml for CoNS. Vitek did not report vancomycin MICs of 1 or 4 g/ml for any of the isolates tested. While the sensitivity of detecting staphylococci with reduced susceptibility to vancomycin appears to be improved with Vitek version 7.01 software, when compared to earlier software versions, laboratories may notice an overall shift in MIC data toward higher vancomycin MICs, although for the most part, this does not affect the categorical interpretations of the results.
Introduction
Vancomycin remains the primary antimicrobial agent for treatment of infections caused by methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci (CoNS) (Chambers, 1997; Gilbert et al., 2001) . However, there have been several recent reports of S. aureus and CoNS with reduced susceptibility to vancomycin associated with treatment failure (Garrett et al., 1999; Hiramatsu et al., 1997; Kim et al., 2000; Sieradski et al., 1999; Smith et al., 1999) . In none of the cases did the vancomycin MICs exceed 16 g/ml, which, by National Committee for Clinical Laboratory Standards (NCCLS) classification, is still considered in the intermediate range. However, concern was raised about the ability of clinical laboratories to detect this emerging resistance problem (Tenover et al. 1998) .
One of the methods frequently used in laboratories to detect decreased susceptibility to vancomycin among isolates of S. aureus and CoNS is the Vitek automated system 1 (bioMérieux, Hazelwood, Mo.). Earlier reports indicated that previous Vitek software versions often reported vancomycin MICs in the NCCLS susceptible range (Յ0.5-4g/ ml) for isolates that by broth microdilution (BMD) demonstrated vancomycin MICs in the intermediate range (8 -16 g/ml) (Tenover et al., 1998) . Vitek recently introduced software version 7.01, which purportedly is more sensitive than earlier software versions in detecting S. aureus and CoNS with reduced susceptibility to vancomycin (Vitek Product Information, 1999) . In our study, we evaluated 143 selected isolates of staphylococci to determine whether the new Vitek software improved detection of staphylococcal isolates with decreased susceptibility to vancomycin.
Materials and methods

Bacterial strains
143 isolates of staphylococci (Table 1 ) from 28 U.S. states and Japan that were submitted to the Centers for Disease Control and Prevention (CDC) or Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) Hubert et al., 1999) resistance phenotypes were selected for antimicrobial susceptibility testing. All but four S. aureus isolates and 16 CoNS isolates were oxacillin-resistant by BMD. The isolates were transferred from -70°C storage onto Trypticase Soy agar plates containing 5% defibrinated sheep blood (BD BioSciences, Sparks, MD) and subcultured a second time before testing. The isolates were identified by catalase and coagulase tests (Staphaurex, Murex, UK) and standard biochemical procedures (Kloos and Bannerman, 1999) .
Study methods
The study was conducted in three phases. In Phase I, two methods, the NCCLS BMD method and the Vitek automated system, were used to determine the vancomycin susceptibility of the study isolates. For BMD, 96-well MIC plates were prepared in-house using NCCLS methods (NC-CLS, 2000) . Vancomycin (Eli Lilly & Co., Indianapolis, IN) was tested at concentrations of 0.06 -128 g/ml. Testing and interpretation were performed according to NCCLS document M7-A5 (NCCLS, 2000) . For the Vitek method, GPS-107 cards and the version 7.01 software were used. Testing was performed following manufacturer's instructions. In Phase II, 139 of the 143 isolates were tested using the Vitek method with both GPS-105 and GPS-107 cards; four isolates were not available for testing. In Phase III, two hospital laboratories in Atlanta (hospitals A and B) that use the Vitek system with software version 7.01 with GPS-106 cards participated in an inter-laboratory MIC comparison using a subset of isolates. Fifteen S. aureus strains for which the broth microdilution MICs were 1 g/ml (seven isolates), 4 g/ml (six), or 8 g/ml (two) were selected. The isolates were subcultured from frozen stocks, transferred to Trypticase Soy agar plates containing 5% defibrinated sheep blood, and incubated at 35°C for 18 h. The isolates were sent to the laboratories where the isolates were subcultured a second time to blood agar plates prior to testing on the Vitek systems.
The quality control strains used for the BMD method were Enterococcus faecalis ATCC 29212, S. aureus ATCC 29213, and S. aureus ATCC 43300. For the Vitek method, the quality control strains used were E. faecalis ATCC 29212, S. aureus ATCC 29213, Escherichia coli ATCC 35218, and E. faecalis ATCC 51299.
Results
Broth microdilution versus Vitek (Phase I )
The vancomycin MIC distributions generated by BMD and the Vitek method using the GPS-107 card are shown in Table 1 . For 143 isolates of S. aureus and CoNS, the BMD method yielded a vancomycin MIC range of 0.25-8 g/ml with a mode of 1 g/ml for both S. aureus and the CoNS. The vancomycin MIC range from the Vitek was Յ0.5-Ն32 g/ml with a mode of Յ0.5 g/ml for S. aureus and 2 g/ml for CoNS. The Vitek did not report vancomycin MICs of 1 or 4 g/ml for any of the study isolates.
On initial testing by BMD, five isolates of S. aureus and five of CoNS demonstrated vancomycin MICs of 8 g/ml (Figure 1) . However, by Vitek testing, vancomycin MICs of 8 g/ml were reported for only two isolates (one S. aureus and one CoNS), although for 19 isolates (12 S. aureus and seven CoNS) the vancomycin MICs were 16 g/ml. Vancomycin MICs of Ն32 g/ml were reported initially for two S. aureus isolates, but the MICs decreased to Յ0.5 g/ml on retesting (Figure 1) .
Of the 23 strains for which the vancomycin MICs were 8 to Ն32 g/ml by Vitek, only nine showed MICs of 8 g/ml by BMD; for the remainder MICs were 2-4 g/ml. The two strains for which the initial Vitek vancomycin MICs were Ն32 g/ml had BMD MIC results of 1 g/ml (which is consistent with the MICs of Յ0.5 g/ml observed after retesting the strains by Vitek). When the vancomycin MIC results from the Vitek and BMD were compared using BMD as the gold standard, the MIC results for 49 (34.3%) isolates were in absolute agreement, 77 (53.8%) were in essential agreement (ϩ/Ϫ one dilution), 14 (9.8%) had a two dilution difference, and three (2.1%) differed by three or more dilutions. Of the 17 MIC comparisons (13 S. aureus, two S. haemolyticus, and two S. epidermidis) that varied by two dilutions or more, two (those with initial MICs of Ն32 g/ml) constituted major errors, 13 were minor errors, and two did not result in categorical errors. The percentage of MIC results for oxacillin-susceptible staphylococci that were classified as categorical errors (10.0%) was similar to the percentage of MIC results for oxacillin-resistant staphylococci also classified as having categorical errors (10.4%). 
GPS-105 versus GPS-107 cards (Phase II)
For 139 isolates, the MIC results obtained using GPS-105 cards were compared with those using GPS-107 cards (Figure 2) . Absolute agreement was shown for MIC results from 129 (92.8%) of the isolates; results for two (1.4%) additional isolates showed essential agreement. For the latter two isolates the GPS-105 card yielded MICs of 16 g/ml for both isolates while the GPS-107 card reported one isolate as Ն32 g/ml and the other as 8 g/ml. Repeat testing of these isolates on the Vitek using GPS-105 and GPS-107 cards demonstrated vancomycin MICs of 16 g/ml for both isolates. (For these isolates, the BMD MICs were 4 and 8 g/ml). For eight (5.8%) isolates (six S. aureus, one S. hominis, and one S. warneri) the MICs reported by the two cards differed by two dilutions. Among these isolates, the MICs reported for the GPS-105 and the GPS-107 cards were Յ0.5 and 2 g/ml (four isolates), 2 and 16 g/ml (two), 2 and Յ0.5 g/ml (one), and 16 and 2 g/ml (one), respectively.
Inter-laboratory comparison of Vitek MIC results (Phase III)
Fifteen isolates from Phases I and II, for which the vancomycin MICs were 1, 4, or 8 g/ml by BMD, were selected for further testing in hospitals A and B by the Vitek system with software version 7.01 using GPS-106 cards (Table 2 ). For six of the 15 isolates that demonstrated BMD MICs of 4 g/ml, hospitals A and B reported MICs by Vitek of 2 g/ml (five) or 16 g/ml (one). For the two isolates with BMD MICs of 8 g/ml, hospital A reported Vitek MICs of 2 g/ml, but hospital B reported MICs of 16 g/ml. Neither hospital reported Vitek MICs for vancomycin of 1 g/ml or 4 g/ml for any of the study isolates, as was true in Phases I and II of this study.
Discussion
Testing staphylococci with reduced susceptibility to vancomycin using automated MIC methods, such as Vitek and Microscan rapid panels, showed poor sensitivity in earlier studies (Tenover et al., 1998) . This study assessed the ability of the new Vitek software Version 7.01 to detect reduced susceptibility to vancomycin in staphylococcal isolates. Our data show that the Vitek was able to detect S. aureus and CoNS isolates with reduced susceptibility to vancomycin; however, MIC results generated by Vitek frequently were higher than those reported by BMD. Vitek vancomycin MICs of Ն32 g/ml were not reproducible. We recommend that all isolates for which the vancomycin MICs are Ն4 g/ml by Vitek testing should be repeated. If the high MICs from Vitek are reproducible, the isolates should be tested using an alternative NCCLS-approved method, such as BMD using a 24-h incubation period, to confirm the resistance phenotype.
Comparison of the vancomycin MIC data between the GPS-105 and GPS-107 cards showed no systematic differences. Therefore, the decision to use the GPS-105 or GPS-107 card can be based on other considerations, such as the variety of other antimicrobial agents that each card has to offer.
Because Vitek software version 7.01 did not report vancomycin MICs of 1 or 4g/ml, the distribution of vancomycin MICs for the Vitek method was quite different from that of the BMD method, and different from those produced by previous versions of the Vitek software in our laboratory. This may result, over time, in an upward shift of vancomycin MICs in a healthcare facility's antibiogram. Although this shift may not change the categorical interpretation of the individual susceptibility test results, the increase may erroneously suggest increasing resistance to vancomycin in a healthcare facility.
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